ArticleJournal of the American Heart Association2026
Balancing Days at Home and Major Adverse Limb Events After Surgical Versus Endovascular Lower-Extremity Revascularization in Chronic Kidney Disease.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe risk-benefit trade-offs after lower-extremity revascularization among older patients with chronic kidney disease remain unclear. We compared how surgical versus endovascular lower-extremity revascularization associates with clinical outcomes that may be valued differently by patients.
methodsWe selected adults aged ≥66 years with chronic kidney disease who underwent lower-extremity revascularization from January 1, 2008, to December 31, 2017, with ≥12 months Medicare Parts A and B before the procedure. The primary outcome was days at home at 30, 180, and 365 days after revascularization. The secondary outcome was major adverse limb events (ie, lower-extremity revascularization or major amputation). We report outcomes as the difference in survived days at home and days lost due to major adverse limb events by restricted mean time lost.
resultsAmong 87 446 patients, 15.3% underwent surgical and 84.7% underwent endovascular revascularization. Surgical revascularization was associated with fewer days at home at 30 days (difference, -8.4 [95% CI, -8.6 to -8.2]), 180 days (difference, -21.2 [95% CI, -22.1 to -20.4]) and 365 days (difference, -31.9 [95% CI, -33.5 to -30.6]) compared with endovascular. Surgical revascularization was associated with fewer days lost to major adverse limb events at 180 days (difference, -6.9 [95% CI, -7.6 to -5.8]) and at 365 days (difference, -17.3 [95% CI, -19.3 to -14.7]).
conclusionsIn this study of older patients with chronic kidney disease, surgical lower-extremity revascularization was associated with fewer survived days at home, but also with fewer days lost to major adverse limb events compared with an endovascular approach. Considering different risk-benefit profiles when planning for lower-extremity revascularization is essential to facilitate shared decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.